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The fund of knowledge regarding the versatility of presentation of MM metastases is still quite incomplete. The recent literature
pertaining to the current understanding of the mechanisms underlying two special features of MM metastasis is reviewed. On
the one hand, a long disease-free interval (MM dormancy) may occur before the surge of overt metastases. On the other hand,
the so-called MM smouldering phenomenon refers to the condition where regional metastases wax and wane for long periods
of time on restricted skin regions. It is important to emphasize that local micrometastases often predict sentinel lymph node
involvement but may not reﬂect progression of the primary MM to full-blown visceral metastatic competence. It is likely that
a combination of factors impacts the versatile MM metastasic progression. Among the main factors, one has to mention the
phenotypic heterogeneity and variability in the phenotype of MM cells, the presence of MM stem cells and MM cells engaged in an
ampliﬁcation proliferation pool, as well as the host immune response, and possibly the induction of a particular stromal structure
and vascularity.
1.Introduction
Limitations in the understanding of the biologic versatility
of malignancies including malignant melanoma (MM) have
resulted in diﬀerent deﬁnitions of even their most funda-
mental terms [1, 2]. In spite of semantic quandaries, MM
is regarded as a single or mixed population of abnormal
melanocytes demonstrating temporally unrestricted growth
preference over the normal cell contingent. MM progression
corresponds to sequential focal changes in the neoplastic cell
population. These events are present from tumor induction
to full blown MM including metastasis. This condition is
accompanied by growth disorganisation and frequent cyto-
logic atypia. The neoplastic melanocytes invade surrounding
tissues, and some are prone to metastasize at distant sites.
Thisprocessleadstoaseriesofqualitativelydiﬀerenttumoral
deposits.
The evolution of MM metastases is typically the result
of tumor progression and their aspects are related to (a) the
malignant cell proliferation kinetics, (b) the antigenic dif-
ferentiation of the cell molecular components, and (c) the
release of growth factors inﬂuencing the peritumoral stroma
including vascularization.
2.MMGrowthRateandMM StemCells
On clinical ground, several groups of patients may be
identiﬁable according to the MM evolution. A ﬁrst group
encompasses primary MM remaining localized for months
or years (slow growing MM). A second group is formed by
MMgrowingrapidlyinamatterofweeks(fastgrowingMM)
[3].Athirdgroupisformedbycompletelyregressedprimary
MM leaving regional metastases (orphan metastases).
On histopathologic ground, the MM growth rate is
related to the proliferative activity of its cells. The mitotic
rate [4, 5], the S-phase index [6] and the growth fraction
representedbytheMIB/Ki-67index[3,7–11]aredistinctbut
somewhat correlated parameters. Globally, a high prolifera-
tive activity in the primary MM irrespective of its thickness2 Dermatology Research and Practice
predicts early metastases to the regional lymph nodes and
beyond [6–8].
The numeration of mitotic ﬁgures, being either below
or above 1/mm2, is advocated by the American Joint Com-
mittee on Cancer (AJCC) group [5]. Unless using historne
immunohistochemistry, some mitotic ﬁgures may be diﬃ-
cult to identify with conﬁdence, and they may be confused
with apoptotic nuclei. Another problem is linked to the
preciseareastobeconsideredintheevaluation.Thediﬃculty
is more prominent in thin MM with jagged borders. The
percentage of Ki67+ nuclei show a much larger range of
values among MM, and thus it is more easy to handle for
discriminating the high and the low risk MM [10, 12].
The balance between cell proliferation and apoptosis is
of paramount importance in the determination of the MM
tumorigenic potential [13]. The proliferative activity of MM
is in part regulated by its tumor vascularity [3, 13–15]. The
inﬂuence of the nonvascular extracellular matrix on MM
progression should not be neglected [16, 17].
The putative role of MM stem cells is increasingly
recognized in the primary MM and its metastases [18–
22]. In general, the antigenic patterns inside primary MM
are variable and heterogeneous [12]. Some markers of
melanocytic stem cells including CD166, CD133, and nestin
are present in MM [20]. Such immunoreactivity likely
corresponds to genetic pathways instrumental to stem cell
biology. Interestingly enough, MM stem cells have a slow
proliferative rate. Thus, they may remain silent for very
long periods of time before initiating an ampliﬁcation
proliferative pool of MM cells revealing overt metastases
[3, 11].
3. MM Progressionandthe Host
MM originating from the skin and subsequently releasing
metastases exhibits some pathologic attributes in relation
to the host. In its early stage of evolution the neoplasm
does not set up any eﬀective and complete immunologic
rejection by the host, otherwise any incipient MM would
be readily destroyed. In fact, the MM cell phenotype is
typically heterogeneous [12] although it looks uniform at
the standard histopathologic examination. With progression
of the neoplasm, any mutant MM cell deprived from the
innate ability to survive and escape the host defences would
be readily destroyed. This process is responsible for partial
MM regression which is so frequent in superﬁcial spreading
MM, occurring either spontaneously or induced by various
forms of immunotherapies [23].
The process of metastasis consists of a series of linked,
sequential steps. Although some of the steps in this process
contain stochastic elements, metastasis as a whole favors the
survival and growth of a few subpopulations of cells that
preexist within the primary neoplasm. Metastases may have
a clonal origin, and diﬀerent metastases possibly originate
fromtheproliferationoffewcells.Theoutcomeofmetastasis
depends on the interaction of metastatic cells with various
host factors. Organ-speciﬁc metastases have been demon-
strated in a variety of neoplasms and may be speciﬁc to a
particularsitewithinagivenorgan.Clonalanalysisofhuman
MM revealed that these neoplasms were heterogeneous for
metastatic properties and that growth in the environment
of speciﬁc organs is selective. These ﬁndings suggest that
systemic physiologic signals are potentially recognized by
neoplastic cells, presumably by mechanisms similar to those
shared by their normal cell counterparts.
A fundamental prerequisite for MM metastases resides
in the ability of MM cells to dissociate from the primary
MM and to breach a series of sequential structural and
functional barriers. The progression of any primary MM
and its metastases has to be adaptable to distinct and
variable environments in order to survive. In all likelihood,
a natural selection of MM cell phenotypes occurs during
MM invasion. The same feature operates in every collection
of metastatic MM cells lodging at diﬀerent body sites [24].
Indeed, the local immune mechanisms may detect and
destroy some metastatic cells. Meanwhile, other metastatic
cells without the same attributes survive. Just as the primary
MM is likely polyclonal, so are the metastases [1].
Any local recurrence at the site of the primary MM
rarely develops simultaneously with disseminated disease.
MM metastases commonly involve body sites where other
cancer metastases are collected, namely the skin, lymph
nodes, and lungs.
The host defences do not apparently achieve the same
eﬃcacy in every tissue. Therefore, it comes about that selec-
tive survival of MM cells is possible in some restricted organs
and tissues. In addition, the host defences may be altered
by immunosuppression [25]. An alternative possibility relies
on the nature of the stroma where metastatic cells are stuck.
Indeed, the stroma abutted to the primary MM exhibits a
peculiar composition [16, 17] that may favor or be necessary
fortheneoplasticsurvivalandgrowth.Iftheseconditionsare
not met at the ﬁnal destination of the metastatic cells, they
may fail to develop overt metastasis.
In a global perspective, the induction of a local microme-
tastatic process does not ineluctably lead to overt metastases
at distance. Indeed, at the onset, the micrometastasis may
be destroyed, remain quiescent even for years, or may grow
under a positive proliferation-apoptosis balance. Typically,
the fate of metastatic MM cells varies in time. Even after a
long period of quiescence, overt metastasis may appear [25].
Theymay alternativelyenteraspontaneous regressionphase.
In some instances, metastases appear in crops, and they grow
in concert as if they were synchronized by a systemic control.
In these instances, their sizes are rather similar at any time in
their evolution. In other circumstances, metastases appear to
grow independently each other. At the extreme, some grow
while others regress in the same time. This feature has been
called the MM smouldering phenomenon [26].
4.MMMicrosatellites
Metastasis is deﬁned as a malignant neoplasm arising from
a primary or metastatic malignancy without remaining no
longer in contiguity with the initial tumor. In the early step
of evolution, MM lesions lack competence for metastasis.
Indeed,selectedmetastaticstepsdependon(a)therateofcell
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Figure 1: Example of DNA ﬂow cytometry in a MM metastasis showing a variable content in cell DNA.
migratingawayfromtheprimarysite,(c)thenumberofcells
entering a venule or a terminal lymphatic, (d) the number
of cells surviving in the blood or lymph vascular pathway,
(e) the number of cells escaping from vascular pathway,
and (f) the number of cells surviving and replicating at the
metastatic site. Any step in the metastatic pathway must
ultimately be related, in some way, to the rate of production
of the cells in the primary MM [1, 4, 9, 10].
Presence of MM microsatellites is associated with
increased overt locoregional metastases [27–30]. It may
represent a signiﬁcant negative predictor for relapse-free
survival. By contrast, microsatellites were variably reported
to decrease [28]o rn o t[ 30] the overall survival. MM
microsatellites appear to be intimately tied to other markers
of MM aggressiveness. This concept was raised for intra-
dermal metastases greater than 0.05mm in diameter [27].
With the introduction of immunohistochemistry, smaller
lesions were possibly identiﬁed down to single cell MM
micrometastases [29]. Flow cytometry searching for DNA
content in MM metastases reaching a millimetric volume
variably reveals the presence of a combination of diploid,
tetraploid, and various other polyploid cells (Figure 1).
A fundamental understanding of mechanisms involved
in MM metastasis has been improved over the past two
decades. Several migration paths for MM micrometastases
were identiﬁed in the skin. These cells may be found inside
somevessellumina[31],insertedwithinvesselwalls[32–34],
abutted to the outer portion of endothelial cells [14, 35–39],
and dispersed inside the stroma [14, 29].
By deﬁnition, cells in a distant metastatic site have full
metastatic competence. Consequently, it seems likely that
metastasis from metastasis is a routine event in neoplastic
biology. However, the role of the stroma hosting MM metas-
tasis is not harmless because a cardinal property of a
malignancy is the ability to grow in the mesenchyme at
the primary and secondary sites. Indeed, the premetastatic
mesenchyme is noticeably diﬀerent from the normal. When
neoplastic progression is active, MM lesions have both a
neoplastic parenchyme and a neoplastic mesenchyme.
As the mesenchyme of the distant site is unprepared and
may require a long period of neoplastic adaptation prior
to signiﬁcant growth. Thus, metastases may be limited to
a single organ or tissue for a certain period of time. Such
patterns of spread may reﬂect the existence of cells only
capable of growth in the mesenchyme speciﬁc to a given
organ or tissue. Common restricted pathways include skin
metastases.
An eventual lack of metastasis could be explained by a
subset of tumors capable of growth in the stroma at the
primary site, but incapable of completion of any step in a
metastatic pathway, except for invasion and some motility in
the dermis. According to such hypothesis invasiveness and
metastatic development would not be acquired in concert,
but as successive cell adaptations.
5. Smouldering MM
The interrelations between the host and MM cells are under
the inﬂuence of a vast array of factors. These events are
probably not static, but result from a continuous ﬂuctuating
balance between two living systems engaged in natural
selection.Thechangesintimeofthecombinationofdiﬀerent4 Dermatology Research and Practice
cell processes including MM and its microenvironment may
lead to a condition named smouldering MM.
The concept of smouldering MM was raised after an
extensive study of MM over more than 20 years, emphasizing
the way by which established metastatic disease may vary
in its evolution [17]. The seminal paper described the
smouldering MM phenomenon as metastases appearing
and disappearing on the same body region over a period
of months or years. The metastases wax and wane in an
apparently haphazard manner, usually reaching at the most
the size of a pea or a bean.
The smouldering MM phenomenon contrasts with the
more common synchronized burst of metastatic crops. This
latter condition has been particularly observed following
excision of a primary MM at a time when the metastatic
diseases remained undisclosed. The smouldering MM high-
lights the fact that tumor progression is not ineluctable.
Indeed, the net directionality of MM metastasis early in
tumor progression may be toward growth or regression. This
may be due to the apoptosis prevalence over proliferation,
the versatility of antitumoral immunity, the lack of stromal
receptivity, and any defect in angiogenesis. Of note, smoul-
dering inﬂammation in the neoplasm microenvironment
promotes proliferation and survival of malignant cells,
angiogenesis, metastasis, subversion of adaptive immunity,
as well as response to hormones, and chemotherapeutic
agents [40]. This multifaceted process possibly ends in a
programmed pathway of apoptosis and necrosis.
The smouldering MM phenomenon probably involves a
combination of distinct cell properties related to site-speciﬁc
MM cell growth, site-speciﬁc adhesion molecules, site-
speciﬁc metastatic cell invasion, and site-speciﬁc regulation
of metastatic cell growth and regression. Novel concepts
regarding early seeding of metastases coupled to parallel
progression, self-seeding of primary tumors by circulating
neoplastic cells, and the induction of premetastatic niches
in distant organs by primary cancers have come to the fore
[41]. Such complex features have been compared to the
development of plant selling [38]. Although many metastatic
neoplasms are able to colonize a wide variety of tissues,
the smouldering MM phenomenon frequently and almost
exclusively occurs in the skin area between the primary MM
and the ﬁrst group of drainage lymph nodes. Hence, there
are regional inﬂuences in the metastatic colony formation
ruling the MM smouldering diseases. The metastatic process
appears to be in a cleft stick.
6. MM Dormancy
Any unusually long latency period between the primary
MM treatment and metastatic occurrence corresponds to a
clinically disease-free condition. It is commonly thought to
represent clinical MM dormancy. The relationship between
such condition and the cause of MM cell dormancy is
complex and probably multifactorial [42]. The process is not
stable and may lead to relapse [43].
Tumoral dormancy and autophagy may be in part
correlated. Autophagy is a homeostatic and catabolic process
that enables the sequestration and lysosomal degradation
of cytoplasmic organelles and proteins. Such process is im-
portant for the maintenance of genomic stability and cell
survival. Autophagy is a mechanism of stress tolerance that
maintains cell viability and possibly leads to tumor dor-
mancy, progression, and therapeutic resistance [44].
Delay of MM metastases is a manifestation suggesting
a host defence mechanism or a peculiar nature of non-
proliferative MM cells possibly involving MM stem cells.
Globally about 40% of patients who develop MM metastases
do so more than 5 years after primary treatment. A typical
example is the appearance of metastases in the liver, many
years after removal of the eye aﬀected by intraocular MM.
The disease-free interval before metastases may be as long
as 25 years. When metastases from uveal MM develop, they
almost always appear ﬁrst in the liver and often are found
only in the liver. This strong tendency to involve the liver
early in the course of the disease is not explained on the basis
of any anatomic or physiologic factors. The reasons for the
long interval from primary treatment to metastases in uveal
melanoma are completely unknown. Since the eye has no
lymphatic drainage, the MM must have already metastasized
prior to the enucleation, and yet a long period of time
may elapse before these metastases appear clinically in the
liver. The rate of growth of these overt metastases varies
considerably once clinically detectable. It is tempting to
speculate that these metastatic implants remain dormant for
many years because of some intrinsic controlling mechanism
of the MM cells themselves or a systemic control by the
host.
Another example of MM dormancy deals with MM de-
veloped from transplant organs in patients placed in im-
munocompromised condition [24, 45, 46]. Micrometastases
that had remained silent in the donor subject develop in
an uncontrolled brisky way when the invaded organ is
transplanted in the immunocompromised recipient.
7. Conclusion
The development of MM metastases is not the expression
of a single uniform process. Many factors linked to the
nature of the neoplastic cells and the reactivity of the host
interfere in a complex way. Smouldering MM reﬂects the
individual life of each metastasis conﬁned to a restricted
skin territory. The lesions wax and wane in an apparently
haphazard and uncoordinated way. MM dormancy refers to
a condition where overt metastases appear after an extended
lag time. The intervention of metastatic MM stem cells or of
metastatic MM cells blocked in the cell cycle of proliferation
is possible.
The two phenomena, that is, the smouldering and the
dorman processes presently described in the MM metastatic
progression might in addition possibly occur at the primary
site. The smouldering primary MM phenomenon could
correspond to the partial MM regression which is a frequent
observation. The primary MM dormancy would correspond
to a lengthy duration between MM initiation and the early
clinical stage of MM duration.
These two conditions are worth studying because new
therapeutic advances could emerge by stirring up andDermatology Research and Practice 5
controlling the smouldering and the dormancy MM phe-
nomena.
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